利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

110 条记录 (耗时 0.023 秒)

    ARYLSULFONIC ACID SALTS OF PYRIMIDINE-BASED ANTIVIRAL AGENTS
    52.
    发明公开
    ARYLSULFONIC ACID SALTS OF PYRIMIDINE-BASED ANTIVIRAL AGENTS 审中-公开
    嘧啶含氮化合物FOR USE AS抗病毒剂的芳基磺酸的盐

    公开(公告)号：EP1248783A1

    公开(公告)日：2002-10-16

    申请号：EP01942363.1

    申请日：2001-01-11

    申请人： Tularik Inc.

    发明人： POWERS, Jay, P.

    IPC分类号： C07D403/04 ,  A61K31/506 ,  A61P31/22

    CPC分类号： C07D231/12 ,  C07D233/56 ,  C07D249/08

    摘要： Salts of pyrimidine derivatives are provided having formula (I), wherein R represents hydrogen, methyl or ethyl; Z represents a substituted or unsubstituted 1-piperidinyl, a substituted or unsubstituted 4-morpholinyl, or a substituted or unsubstituted 1-pyrrolidinyl; and Ar represents a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl. These salts are particularly useful as antiviral agents (e.g., to treat CMV infections).

    I-(KAPPA)- B(KINASES)
    55.
    发明公开
    I-(KAPPA)- B(KINASES) 失效
    我（KAPPA）-B激酶

    公开(公告)号：EP1017786A1

    公开(公告)日：2000-07-12

    申请号：EP98909030.3

    申请日：1998-03-06

    申请人： TULARIK, INC.

    发明人： CAO, Zhaodan

    IPC分类号： C12N1/14 ,  C12N1/20 ,  C12N5/00 ,  C12N15/00 ,  C12N9/12 ,  C07H21/04 ,  C12Q1/48

    CPC分类号： G01N33/6872 ,  A61K38/00 ,  C07K14/4702 ,  C12Q1/48 ,  G01N2500/00

    摘要： The invention provides methods and compositions relating to IλB regulating proteins, known as T2K proteins, and related nucleic acids. The proteins may be produced recombinantly from transformed host cells from the disclosed T2K encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed T2K gene, T2K-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

    Interleukin 4 signal transducers and binding assays
    56.
    发明公开
    Interleukin 4 signal transducers and binding assays 失效
    白细胞介素-4的信号转导子和结合测定

    公开(公告)号：EP0692488A3

    公开(公告)日：1999-03-17

    申请号：EP95304715.6

    申请日：1995-07-05

    申请人： TULARIK, INC.

    发明人： McKnight, Steven L. ,  Hou, Jinzhao

    IPC分类号： C07K14/47 ,  C07K14/715 ,  C07K16/18 ,  G01N33/68

    CPC分类号： C07K14/4705 ,  A61K38/00 ,  C07K14/705 ,  C12Q1/6897 ,  G01N33/6869

    摘要： The invention provides methods and compositions for identifying pharmacological agents useful in the diagnosis or treatment of disease associated with the expression of a gene modulated by an interleukin 4 signal transducer and activator of transcription, IL-4 Stat. IL-4 Stat peptides and IL-4 receptor peptides and nucleic acids encoding such peptides find therapeutic uses. The subject compositions include IL-4 Stat and IL-4 receptor proteins, portions thereof, nucleic acids encoding them, and specific antibodies. The disclosed pharmaceutical screening methods are particularly suited to high-throughput screening where one or more steps are performed by a computer controlled electromechanical robot comprising an axial rotatable arm.

    TRANSCRIPTION FACTOR-DNA BINDING ASSAY
    57.
    发明公开
    TRANSCRIPTION FACTOR-DNA BINDING ASSAY 失效
    转录因子的DNA结合分析

    公开(公告)号：EP0715656A4

    公开(公告)日：1998-11-25

    申请号：EP95917734

    申请日：1995-04-25

    申请人： TULARIK INC

    发明人： PETERSON MICHAEL G ,  BAICHWAL VIJAY R ,  STRULOVICI BERTA

    IPC分类号： G01N33/566 ,  C12N15/09 ,  C12Q1/68 ,  C12Q1/70 ,  G01N33/50

    CPC分类号： G01N33/5008 ,  C12Q1/6811 ,  C12Q1/6813 ,  C12Q1/6876 ,  C12Q1/701 ,  C12Q2600/136

    摘要： Pharmacological agents active at the level of gene transcription are identified in high throughput drug screening assays. The methods involve combining a labeled transcription factor, a nucleic acid coupled to a ligand, a candidate pharmacological agent and a receptor immobilized on a solid substrate, such as a microtiter plate, filter, or bead. The nucleic acid has at least that portion of a nucleotide sequence naturally involved in the regulation of the transcription of the gene which is necessary for sequence-specific interaction with the transcription factor. The resultant combination is incubated under conditions whereby the receptor is bound to the ligand and, but for the presence of said candidate pharmacological agent, the transcription factor is sequence-specifically bound to the nucleic acid. Unbound transcription factor is then removed or washed from the solid substrate and labelled, sequence-specifically bound transcription factor is detected. Incubates which include candidate agents which alter transcription factor binding deviate from control incubates in terms of label signal - typically, binding is disrupted and the signal is diminished. In a preferred embodiment, the entire process is performed by a computer-controllable electromechanical robot with an axial rotatable arm.